Cargando…
Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status
BACKGROUND: Neurofilament light chain (NF-L) levels reflect axonal damage in different conditions, including demyelinating disorders. OBJECTIVES: We aimed to compare serum NF-L levels in patients with aquaporin-4 antibodies (AQP4-Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative cases...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703099/ https://www.ncbi.nlm.nih.gov/pubmed/29204292 http://dx.doi.org/10.1177/2055217317743098 |
_version_ | 1783281640610463744 |
---|---|
author | S, Mariotto A, Farinazzo S, Monaco A, Gajofatto G, Zanusso K, Schanda R, Capra C, Mancinelli A, Bonora R, Bombardi M, Reindl S, Ferrari |
author_facet | S, Mariotto A, Farinazzo S, Monaco A, Gajofatto G, Zanusso K, Schanda R, Capra C, Mancinelli A, Bonora R, Bombardi M, Reindl S, Ferrari |
author_sort | S, Mariotto |
collection | PubMed |
description | BACKGROUND: Neurofilament light chain (NF-L) levels reflect axonal damage in different conditions, including demyelinating disorders. OBJECTIVES: We aimed to compare serum NF-L levels in patients with aquaporin-4 antibodies (AQP4-Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative cases with neuromyelitis optica spectrum disorders and related disorders. METHODS: We analysed AQP4-Ab and MOG-Ab with cell-based assay and NF-L with ultrasensitive electrochemiluminescence immunoassay. RESULTS: Median NF-L levels were increased in 25 AQP4-Ab-positive patients (59 pg/ml) as compared with 22 MOG-Ab-positive cases (25 pg/ml), 52 seronegative patients (18 pg/ml), 25 multiple sclerosis patients (12 pg/ml) and 14 healthy controls (12 pg/ml). CONCLUSIONS: Increased serum levels of NF-L in patients with AQP4-Ab or MOG-Ab might reflect an ongoing axonal damage and a more malignant disease course. |
format | Online Article Text |
id | pubmed-5703099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-57030992017-12-04 Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status S, Mariotto A, Farinazzo S, Monaco A, Gajofatto G, Zanusso K, Schanda R, Capra C, Mancinelli A, Bonora R, Bombardi M, Reindl S, Ferrari Mult Scler J Exp Transl Clin Short Report BACKGROUND: Neurofilament light chain (NF-L) levels reflect axonal damage in different conditions, including demyelinating disorders. OBJECTIVES: We aimed to compare serum NF-L levels in patients with aquaporin-4 antibodies (AQP4-Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative cases with neuromyelitis optica spectrum disorders and related disorders. METHODS: We analysed AQP4-Ab and MOG-Ab with cell-based assay and NF-L with ultrasensitive electrochemiluminescence immunoassay. RESULTS: Median NF-L levels were increased in 25 AQP4-Ab-positive patients (59 pg/ml) as compared with 22 MOG-Ab-positive cases (25 pg/ml), 52 seronegative patients (18 pg/ml), 25 multiple sclerosis patients (12 pg/ml) and 14 healthy controls (12 pg/ml). CONCLUSIONS: Increased serum levels of NF-L in patients with AQP4-Ab or MOG-Ab might reflect an ongoing axonal damage and a more malignant disease course. SAGE Publications 2017-11-22 /pmc/articles/PMC5703099/ /pubmed/29204292 http://dx.doi.org/10.1177/2055217317743098 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Short Report S, Mariotto A, Farinazzo S, Monaco A, Gajofatto G, Zanusso K, Schanda R, Capra C, Mancinelli A, Bonora R, Bombardi M, Reindl S, Ferrari Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status |
title | Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status |
title_full | Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status |
title_fullStr | Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status |
title_full_unstemmed | Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status |
title_short | Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status |
title_sort | serum neurofilament light chain in nmosd and related disorders: comparison according to aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies status |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703099/ https://www.ncbi.nlm.nih.gov/pubmed/29204292 http://dx.doi.org/10.1177/2055217317743098 |
work_keys_str_mv | AT smariotto serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT afarinazzo serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT smonaco serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT agajofatto serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT gzanusso serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT kschanda serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT rcapra serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT cmancinelli serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT abonora serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT rbombardi serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT mreindl serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus AT sferrari serumneurofilamentlightchaininnmosdandrelateddisorderscomparisonaccordingtoaquaporin4andmyelinoligodendrocyteglycoproteinantibodiesstatus |